MeMed Diagnostics Ltd. has created a platform for discovery, development and validation of novel diagnostic solutions aimed at improving the management of patients with infectious diseases and inflammatory disorders. The platform relies on a combination of molecular and cellular immunology, bioinformatics, big data analysis and clinical knowledge. MeMed’s products provide physicians with critical, timely information that supports decision making on the treatment of patients. The company’s lead product that allows to differentiate between bacterial and viral infections was approved for use by the FDA in late 2021.